⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705223 | 1.00 | — | — | |
| SCHEMBL15526376 | 0.83 | HRH1 (0.50) | — | |
| SCHEMBL2170011 | 0.79 | HRH1 (0.46) | — | |
| SCHEMBL2299751 | 0.79 | — | — | |
| SCHEMBL29898951 | 0.79 | — | — | |
| SCHEMBL13097030 | 0.78 | KDM4E (0.38) | — | |
| Hydrochloric Acid SCHEMBL1872727 | 0.78 | HRH1 (0.44) | — | |
| SCHEMBL23235054 | 0.77 | — | — | |
| SCHEMBL1879544 | 0.77 | — | — | |
| SCHEMBL3196761 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4522280-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066354-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12139487-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| EP-2012791-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007092496-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| CN-1934082-A | Organic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-21 | — | — | CN | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1699762-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |